Cytotoxic and targeted therapy for BRCA1/2-driven cancers.

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Germline BRCA1/2 mutations lead to tumors sensitive to DNA-damaging agents like platinum compounds and PARP inhibitors (PARPi).
• Acquired resistance to platinum/PARPi therapy occurs due to restoration of BRCA1/2 function, necessitating alternative treatment approaches.

Purpose of the Study:

• To explore novel therapeutic strategies for BRCA1/2-mutated and BRCAness tumors.
• To address challenges in predicting drug sensitivity and optimizing treatment sequencing.

Main Methods:

• Review of existing literature on BRCA1/2-mutated cancers and treatment responses.
• Analysis of preclinical and clinical data on immunotherapy and combination therapies.
• Discussion of diagnostic challenges and the need for rapid predictive assays.

Main Results:

• BRCA1/2-mutated tumors exhibit increased immunogenicity, suggesting potential efficacy of immune therapies.
• Combination therapies or high-dose chemotherapy may enhance tumor response.
• Cross-resistance between platinum compounds and PARPi is a concern, requiring careful treatment planning.
• Sporadic tumors with BRCAness share drug sensitivity profiles with hereditary cancers.

Conclusions:

• Development of alternative treatment strategies beyond platinum/PARPi is essential for managing resistance.
• Immunotherapy and novel drug combinations show promise for BRCA1/2-driven tumors.
• Advancements in BRCAness testing and reduced turnaround times for predictive assays are critical for personalized cancer care.